Hikal launches HPAPI laboratory at Integrated Innovation Centre, Pune

The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements

AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025

New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers

Merck advances cancer innovation by expanding role of Keytruda across new tumor

The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025

Lonza receives Swissmedic approval for Biologics drug product filling line in Stein

New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain

Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer

BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion

Lilly to build $5 billion manufacturing facility in Virginia

This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year

Mycenax and Spera forge alliance to streamline ADC drug substance

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site